Bhidayasiri Roongroj, Tarsy Daniel
Chulalongkorn University Hospital, Chulalongkorn Comprehensive Movement Disorders Center, Division of Neurology, 1873 Rama 4 Road Bangkok 10330, Thailand.
Expert Rev Neurother. 2006 Jun;6(6):863-86. doi: 10.1586/14737175.6.6.863.
Dystonia may be a sign or symptom, that is comprised of complex abnormal and dynamic movements of different etiologies. A specific cause is identified in approximately 28% of patients, which only occasionally results in specific treatment. In most cases, treatment is symptomatic and designed to relieve involuntary movements, improve posture and function and reduce associated pain. Therapeutic options are dictated by clinical assessment of the topography of dystonia, severity of abnormal movements, functional impairment and progression of disease and consists of pharmacological, surgical and supportive approaches. Several advances have been made in treatment with newer medications, availability of different forms of botulinum toxin and globus pallidus deep brain stimulation (DBS). For patients with childhood-onset dystonia, the majority of whom later develop generalized dystonia, oral medication is the mainstay of therapy. Recently, DBS has emerged as an effective alternative therapy. Botulinum toxin is usually the treatment of choice for those with adult-onset primary dystonia in which dystonia usually remains focal. In patients with secondary dystonia, treatment is challenging and efficacy is typically incomplete and partially limited by side effects. Despite these treatment options, many patients with dystonia experience only partial benefit and continue to suffer significant disability. Therefore, more research is needed to better understand the underlying cause and pathophysiology of dystonia and to explore newer medications and surgical techniques for its treatment.
肌张力障碍可能是一种体征或症状,由不同病因引起的复杂异常动态运动组成。约28%的患者可明确具体病因,而这仅偶尔会带来特异性治疗。在大多数情况下,治疗是对症性的,旨在缓解不自主运动、改善姿势和功能并减轻相关疼痛。治疗方案取决于对肌张力障碍部位、异常运动严重程度、功能损害及疾病进展的临床评估,包括药物、手术及支持性方法。在使用新型药物治疗、不同形式肉毒毒素的可及性以及苍白球深部脑刺激术(DBS)方面已取得多项进展。对于儿童期起病的肌张力障碍患者(其中大多数后来会发展为全身性肌张力障碍),口服药物是主要治疗手段。最近,DBS已成为一种有效的替代疗法。肉毒毒素通常是成人起病的原发性肌张力障碍患者的首选治疗方法,此类患者的肌张力障碍通常局限于局部。对于继发性肌张力障碍患者,治疗具有挑战性,疗效通常不完全,且部分受到副作用的限制。尽管有这些治疗选择,但许多肌张力障碍患者仅获得部分益处,仍遭受严重残疾。因此,需要更多研究来更好地理解肌张力障碍的潜在病因和病理生理学,并探索新的药物和手术技术用于其治疗。